Physician profile
Michael Kamiel
NPI 1669471603
$2,525.58
in general payments reported to CMS, 2019-2025
14 companies · $659 in 2025
The $659 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $132 · 2021: $47.59 · 2022: $378 · 2023: $510 · 2024: $511 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $631.01 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $416.14 | 2023-2025 | |
| Amgen INC. | $320.76 | 2025 | Tepezza |
| Lilly USA, LLC | $252.91 | 2021-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.29 | 2024 | Jardiance, Synjardy |
| Paratek Pharmaceuticals, INC. | $138.83 | 2023-2025 | Nuzyra |
| Vifor Pharma, INC. | $125.96 | 2024 | Veltassa |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | |
| Glaxosmithkline, LLC. | $124.07 | 2023 | Jesduvroq |
| Gilead Sciences, INC. | $112.17 | 2024 | Vemlidy |
| Horizon Therapeutics Plc | $58.65 | 2019-2021 | |
| Abbott Laboratories | $27.55 | 2023 | Freestyle Libre 2 |
| Novo Nordisk INC | $24.22 | 2022 | |
| Madrigal Pharmaceuticals | $17.03 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kamiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.